TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05809336
Drug: PD-1/PD-L1 inhibitor ,chemotherapy/targeting
Approvals — FDA: no, EMA: no, PMDA: no
Description: PD-1/PD-L1 inhibitor ± chemotherapy/targeting
Study: NCT00296387
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00641173
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: treatment with placebo
Study: NCT01728623
Drug: E7080 capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: E7080 is administered as continuous once daily dosing in an uncontrolled manner
Study: NCT02787447
Drug: TKI
Normalized name: Catkin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gefitinib 250mg po qd or Erlotinib 150mg po qd or Icotinib 125mg po tid
Study: NCT02787447
Drug: Thymosin Alpha 1
Normalized name: Thymosin alpha 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initiating thymosin alpha 1 therapy(1.6mg, qd, d1-d14;1.6mg, biw, d15-d90) at the second week of radiotherapy.
Study: NCT00532246
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01928680
Drug: Cisplatin/Capecitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin/Capecitabine: Capecitabine 1000mg/m2 orally Bid on day 1 to day 14 plus Cisplatin 75mg/m2 on day1 of each 21 day cycle, until progression or untolerable toxicity
Study: NCT01580683
Drug: Ascorbic Acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Two 1 g capsules the evening prior to surgery, followed by one 1 g capsule every 12 hours starting the morning of the first postoperative day for 5 days.
Study: NCT04138342
Drug: Topical approved placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo group will receive topical FDA approved in different dosage forms as a negative control drug.
Study: NCT00020722
Drug: Cyclophosphamide, Thiotepa, Carboplatin (CTC) or STAMP V (CTC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide will be given at a dose of 2000 mg/m2 in NS IV over one hour daily on days -4, -3, and -2 (total = 6000 mg/m2).~Thiotepa will be given at a dose of 167 mg/m2 in NS IV over one hour daily on days -4, -3, -2 (total = 500 mg/m2) as the preparative regimen followed by PBSCT on day 0.~Carboplatin will be given at a dose of 267 mg/m2 in D5W IV over one hour daily on days -4, -3, and -2.~Mesna will be administered per BMT Standard of Care Guidelines at a dose of 25% of the total cyclophosphamide dose 30 minutes prior to and then 3, 6, and 9 hours after cyclophosphamide daily on days -4, -3, and -2 prior to PBSCT for a total of 2000mg/m2.
Study: NCT03363659
Drug: Disulfiram
Normalized name: Disulfiram
DrugBank: Disulfiram (DB00822)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Disulfiram is taken orally, twice daily.
Study: NCT04543812
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo will be provided as a 1g tablet. All intervention doses will be based on hemoglobin levels.
Study: NCT01130168
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, capsule taken orally once daily during 4 weeks of treatment
Study: NCT01130168
Drug: Comparator: ISMN ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: ISMN ER 30 mg capsule, taken orally as single daily dose for 4 weeks
Study: NCT02087215
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03990636
Drug: Metil 5-aminolevulinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scrubbing lip vermillion and applying the medication or placebo that is activated (or not, in case of placebo) with red light.
Study: NCT00177021
Drug: Aldara Cream 5%
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03075956
Drug: 5 mg E4 single-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single oral dose of 5 mg E4 will be administered during Period 1 of the study.
Study: NCT03075956
Drug: 15 mg E4 single-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single oral dose of 15 mg E4 will be administered during Period 1 of the study.
Study: NCT03075956
Drug: 45 mg E4 single-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single oral dose of 45 mg E4 will be administered once orally during Period 1 of the study
Study: NCT01283022
Drug: MVI 200
Normalized name: alpha-tocopherol acetate / ascorbic acid / biotin / dexpanthenol / ergocalciferol / folic acid / niacinamide / pyridoxine hydrochloride / riboflavin / thiamine hydrochloride / vitamin A / vitamin B12 / vitamin K1 Injectable Solution [MVI Pediatric]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose reservoir of 200 mcg of misoprostol in a hydrogel polymer vaginal insert within a retrieval system. The MVI 200 will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.
Study: NCT03075956
Drug: 15 mg E4 multiple-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg E4 will be administered once daily orally for 14 consecutive days during Period 2 of the study
Study: NCT02635386
Drug: EQW plus DAPA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg SC injection every 7 days One pill (10 mg) by mouth QD in am
Study: NCT01216293
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo-matching capsules
Study: NCT04302129
Drug: Multimodal analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac 0.75 mg/ Kg and paracetamol 10 mg/ Kg intravenously
Study: NCT01159522
Drug: SCB01A
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is an open-label, single-arm, dose-escalation, safety and tolerability study. Eligible subjects will be assigned to a SCB01A dose level at the time of study entry and scheduled to receive two treatment cycles with SCB01A for the observation of DLT. A treatment cycle is defined as a three-hour infusion of SCB01A given every 21 days. Unless any off-study criteria are met, the study period of each subject can be up to two cycles.
Study: NCT04592081
Drug: Dextenza 0.4Mg Ophthalmic Insert
Normalized name: Dextenza 0.4mg Ophthalmic Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextenza 0.4Mg Ophthalmic Insert
Study: NCT04730674
Drug: tetracycline mixed with xylocaine
Normalized name: Xylocaine with Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 cc of saline containing 2 gm of tetracycline mixed with 5 ml of 2% xylocaine (as a pain relieving agent) was injected at the seroma bed.
Study: NCT00298675
Drug: BSI-201 (iniparib)
Normalized name: CENTRAL LINE DRESSING ERASE BSI CHANGE KIT MEDLINE #BSIPICC1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: BSI-201 administered intravenously (IV), 2x weekly
Study: NCT01338558
Drug: mFOLFOX6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard mFOLFOX6 chemotherapy, 2-week cycles until disease progression, unacceptable toxicity or withdrawal of consent
Study: NCT02970097
Drug: 20ml bolus of 0.5% ropivicaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: local anesthetic
Study: NCT02970097
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 50-100 mcg of medication given intravenously before nerve block
Study: NCT03770013
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: add placebo 9normal saline)
Study: NCT01633086
Drug: nitric oxide gel
Normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1. st gel: sodium nitrites,BID local use X 28 days~2. nd gel: maleic/ascorbic acids ,BID local use X 28 days
Study: NCT01633086
Drug: placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo gel,BID local use X 28 days
Study: NCT01163903
Drug: doxorubicin hydrochloride injection
Normalized name: Doxorubicin Hydrochloride Injection
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 60 mg/m2, IV, scheduled on day 1 of every 3-week interval, 30-60 (±5) minutes after pantoprazole administration.
Study: NCT03549234
Drug: Erector Spinae (single injection)
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.5% (with epinephrine 1:200,000-400,000) will be administered via the needle into the target plane.
Study: NCT03549234
Drug: Paravertebral (single injection)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.5% (with epinephrine 1:200,000-400,000) will be administered via the needle into the target plane.
Study: NCT02110446
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo is composed of corn starch, pigment and minimal dose of 1% SS-1. Patients take 6 gram of experiment medicine three times per day.
Study: NCT02391935
Drug: RCS-01
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cultured, autologous hair follicle cells suspended in cryomedium
Study: NCT02391935
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cryomedium
Study: NCT03687268
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00665990
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide 50 mg/m2 PO once daily increasing in combination with Bevacizumab and Sorafenib until maximum tolerated dose
Study: NCT05245604
Drug: TJO-087
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine ophthalmic nano-emulsion 0.08%, 1 drop once daily
Study: NCT02047565
Drug: 25 IU/kg Beriplex P/N
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02047565
Drug: 10 IU/kg Beriplex P/N
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02732093
Drug: Na.Cl 0.9% (placebo)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02762344
Drug: heparin
Normalized name: Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: routinary heparin administration during coronary angiography/PCI
Study: NCT02942680
Drug: acetylsalicylic acid started for 24 hours before surgery
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02942680
Drug: acetylsalicylic acid stayed for 5 days before surgery
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00749385
Drug: PN 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single tablet containing delayed-release naproxen (500mg) plus immediate-release esomeprazole (20mg)
Study: NCT00749385
Drug: EC naproxen plus EC esomeprazole
Normalized name: esomeprazole
DrugBank: Esomeprazole (DB00736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enteric-coated naproxen tablet (500mg) plus enteric-coated esomeprazole capsule (20mg)
Study: NCT00749385
Drug: EC naproxen
Normalized name: Naproxen 375 MG Oral Tablet, Enteric Coated [EC NAPROXEN]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteric-coated naproxen tablet (500mg)
Study: NCT00827554
Drug: LMWH
Normalized name: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nadroparin Ca 4100 AXa iu twice daily lasted for 6 weeks
Study: NCT03366220
Drug: Balanced crystalloids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care using balanced crystalloids (Iso-Lyte or Plasma-Lyte) only will follow Surviving Sepsis Campaign guidelines. Controls will receive 30 mL/kg (2100 mL in a typical 70 kg adult) of crystalloids within the first 3 hours. Subsequent resuscitation with balanced crystalloids will be titrated to the endpoints of resuscitation.
Study: NCT00553202
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00553202
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01398462
Drug: CWP232291
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV Infusion
Study: NCT01096576
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: orally twice daily for 5 days
Study: NCT00003477
Drug: Antineoplaston therapy (Atengenal + Astugenal)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Children with a visual pathway glioma, which is not amenable to standard therapy or has not responded to standard therapy, will receive Antineoplaston therapy (Atengenal + Astugenal).
Study: NCT00358982
Drug: MGCD0103
Approvals — FDA: no, EMA: no, PMDA: no
Description: MGCD0103 administered orally three times per wek
Study: NCT00675194
Drug: Cisplatin, Irinotecan, Capecitabine
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01200537
Drug: Estradiol
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This group of patients will receive estradiol patches prior to the IVF cycle.
Study: NCT01061437
Drug: PACx14
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard 14 day, 3 drug regimen: lansoprazole, amoxicillin, clarithromycin (PACx14)
Study: NCT01061437
Drug: PACMx5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant therapy - 5 day, 4 drug regimen: lansoprazole, amoxicillin, clarithromycin, metronidazole (PACMx5)
Study: NCT01061437
Drug: PAx5/PCMx5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential Therapy - 10 day, 4-drug regimen: lansoprazole, amoxicillin for 5 days, followed by lansoprazole, clarithromycin and metronidazole for 5 days (PAx5/PCMx5)
Study: NCT01478113
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo will match the dextroamphetamine in form, dosage, frequency, and duration.
Study: NCT02318719
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02318719
Drug: DS-5565
Normalized name: Uretron DS
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00073879
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00423293
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000 mg/m\^2/day 96-hour continous infusion (M-F) starting on day 1 and again on day 29 of radiation therapy.
Study: NCT04492813
Drug: Pharmacokinetic of propofol and remifentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacokinetic of propofol and remifentanil in both population: Obese and non Obese patients
Study: NCT02554383
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo made to match the study antibiotic given twice a day orally for 10 days
Study: NCT00157651
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo for warfarin, adjusted according to sham INR generated by unblinded warfarin monitor
Study: NCT02208570
Drug: Volume loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyethyl starch solution 6ml/kg iv injection
Study: NCT03900429
Drug: MGL-3196
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet
Study: NCT03900429
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Tablets
Study: NCT00370643
Drug: human regular insulin
Normalized name: Human regular insulin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01876615
Drug: YH4808
Approvals — FDA: no, EMA: no, PMDA: no
Description: experimental drug
Study: NCT01876615
Drug: Diclofenac
Normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Depain tablet 25mg
Study: NCT01876615
Drug: YH4808+Diclofenac
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01390350
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150mg subcutaneous injections on day 0
Study: NCT03128528
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each patient, after the run-in/wash-out phase, will be randomly assigned in a doubleblind fashion to one of the two treatment sequences according to a randomisation list.~and provided by the sponsor.
Study: NCT02910843
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: • Capecitabine: day 1 to 38 (5 weeks and 3 days, including Saturday and Sunday) according to dose escalation table. The intake stops in the evening of the last day of RT.
Study: NCT00691600
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo caps or suspension every 12 hours for 10 days
Study: NCT03376802
Drug: SAR425899
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous
Study: NCT03376802
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous
Study: NCT01124838
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by subcutaneous injection
Study: NCT00249782
Drug: Vehicle control, 2x/day
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00249782
Drug: ACZONE (dapsone) Gel, 5%, 2x/day
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00249782
Drug: ACZONE (dapsone) Gel, 5%, 1x/day
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00249782
Drug: MetroGel® (metronidazole gel), 1.0% 1x/day
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00249782
Drug: ACZONE (dapsone) Gel, 5%, 1x/day (AM) + MetroGel (metronidazole gel), 1.0%, 1x/day (PM)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01076764
Drug: Placebo (for Otamixaban)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: Intravenous (IV) solution~Route of administration: IV bolus followed by continuous IV infusion
Study: NCT01076764
Drug: UFH
Normalized name: Ibrufhalal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: Intravenous (IV) solution~Route of administration: IV bolus followed by continuous IV infusion
Study: NCT00404885
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: PO BID
Study: NCT01299116
Drug: Implanon®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subdermal contraceptive implant, marketed in the US as Implanon® or Nexplanon® (containing 68 mg of etonogestrel)
Study: NCT00170404
Drug: Folic Acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01550523
Drug: IGF-1R/AS ODN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive approximately 10 to 20 million IGF-1R/AS ODN treated tumor cells, encapsulated in diffusion chambers (maximum of 10), and re-implanted in the patient's abdomen within 24 hours after the surgery for a 24 hour period.
Study: NCT03082755
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 to 2 Placebo Oral Tablets will be administered once a day in the evening (about 5pm) for 8 weeks.
Study: NCT01299116
Drug: ParaGard®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrauterine device marketed in the US as ParaGard® (a T-shaped plastic device containing 380mm2 of copper surface)
Study: NCT00002463
Drug: MOPP Regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate, Mechlorethamine, Vincristine, Prednisone, and Procarbazine (MMOPP)
Study: NCT00002463
Drug: Leucovorin Calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00002463
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00130845
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00624910
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo sponge contains 70 mg Type I collagen. A total of 3 sponges will be implanted during surgery; one sponge divided between areas in the vault, one sponge divided and placed across the incision in the peritoneum and the final sponge divided and placed between the sheath and skin around the incision.
Study: NCT03375580
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20mg simvastatin, PO qn
Study: NCT02369861
Drug: Refresh Lubricant Eye Drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ocular application 4 timer per day
Study: NCT02134119
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar pill manufactured to mimic dietary supplement
Study: NCT03232320
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (Normal saline)
Study: NCT02019784
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Oral Tablet
Study: NCT02355522
Drug: KY jelly
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01299116
Drug: Mirena®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrauterine system, marketed in the US as Mirena® (containing 52 mg of levonorgestrel)
Study: NCT00002492
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002492
Drug: isolated limb perfusion
Normalized name: ISOLATE
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01445795
Drug: Placebo QD Fasted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule QD fasted x7 days
Study: NCT01445795
Drug: Placebo QD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule Placebo QD dosed with ribavirin x7 days (ribavirin will be dosed in a weight-based fashion as labeled BID)
Study: NCT01445795
Drug: 100 mg INX-08189 with low-fat meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: INX-08189 100 mg capsule, with low-fat meal QD for seven days
Study: NCT01445795
Drug: Placebo with low-fat meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule administered with a low-fat meal QD for seven days
Study: NCT01445795
Drug: Placebo BID Fasted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo BID fasted x7 days
Study: NCT02629003
Drug: [11C]Cimbi-36
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02629003
Drug: [11C]Cimbi-36-5
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00770224
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00770224
Drug: doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04718311
Drug: Oral lichen clinical Healing evaluation
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatments were topically applied for 5 days
Study: NCT01153360
Drug: liothyronine sodium
Normalized name: Liothyronine Sodium
DrugBank: Liothyronine (DB00279)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: liothyronine sodium 20ug, every 12hour (before anesthetic induction, total 4 times)
Study: NCT01153360
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: vitamin B12